News | July 07, 2023
Dabur India expects 10%+ consolidated growth in Q1 FY24
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
The company has received Export Performance Award - API & Intermediaries Gold Star for the year 2021-22
Collaboration to provide hospitals with a comprehensive offering across imaging and treatment for cancer patients requiring radiation therapy
PrecisionLife to analyse OXEGENE data to improve mechanistic understanding of endometriosis and identify novel drug targets to support the development of new personalised treatments
Introduces a line-up of brands targeting key therapeutic categories for its ophthalmology segment launc
The 'A+' rating reflects IOL's robust business model, diversified product portfolio
Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
PEEK brings a new quality to dental care for patients
Pratima takes on the role of Country Speaker in addition to her role as GM and MD of Merck Specialties in India
Subscribe To Our Newsletter & Stay Updated
